StratDeck

Two stocks in Drug Manufacturers - General

AbbVie vs Gilead Sciences: profit, growth, debt and price compared

AbbVie is stronger on 3 of 6 figures: profit margin, sales growth and dividend. Gilead Sciences is stronger on 2: price for its expected profit and price trend.

Figures as of 18 November 2026SEC EDGARYahoo Finance
Explore AbbVie's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

AbbVie and Gilead Sciences side by side
AbbVieABBVGilead SciencesGILD
Net marginStronger: 15.7%−12.5%
Revenue growth, past yearStronger: +10.32%+6.83%
Debt to equity—202.5%
Forward P/E17.6×Stronger: 16.6×
Dividend yieldStronger: 2.42%1.92%
AnalystsBuy · 26Buy · 26
From its 200-day average+15.5%Stronger: +19.3%

Share price over the past year

  • AbbVie+22.3%
  • Gilead Sciences+32.9%

18 Nov 202518 Nov 2026

AbbVie or Gilead Sciences: which is stronger?

  • ABBV

    Which is more profitable?

    AbbVie keeps more of each sale as profit: 15.7% against −12.5%.

  • ABBV

    Which is growing its sales faster?

    AbbVie is growing its sales faster: +10.32% over the past year, against +6.83%.

  • GILD

    Which costs less for the profit it is expected to make?

    Gilead Sciences costs less for the profit it is expected to make: 16.6× its forward earnings, against 17.6×.

  • ABBV

    Which pays more in dividends?

    AbbVie pays more back in dividends for what a share costs: 2.42% a year, against 1.92%.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • GILD

    Which is in the stronger price trend?

    Gilead Sciences' price is in the stronger trend: 19.3% above its 200-day average, against 15.5% above.

What each company does

ABBVAbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Reports results on 3 February 2027

GILDGilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Reports results on 9 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.